BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 24508213)

  • 1. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
    Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
    Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
    Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.
    Bandari RP; Carmack TL; Malhotra A; Watkinson L; Fergason Cantrell EA; Lewis MR; Smith CJ
    J Med Chem; 2021 Feb; 64(4):2151-2166. PubMed ID: 33534560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
    Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bombesin analogues for gastrin-releasing peptide receptor imaging.
    Nanda PK; Pandey U; Bottenus BN; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Smith CJ
    Nucl Med Biol; 2012 May; 39(4):461-71. PubMed ID: 22261143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
    Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
    Liu Z; Yan Y; Liu S; Wang F; Chen X
    Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
    Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
    J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.
    Prasanphanich AF; Nanda PK; Rold TL; Ma L; Lewis MR; Garrison JC; Hoffman TJ; Sieckman GL; Figueroa SD; Smith CJ
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12462-7. PubMed ID: 17626788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Preclinical Evaluation of
    Makris G; Bandari RP; Kuchuk M; Jurisson SS; Smith CJ; Hennkens HM
    Mol Imaging Biol; 2021 Feb; 23(1):52-61. PubMed ID: 32886303
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.